Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on December 21, 2018, 10:40:46 am

Title: Switch From Viread to Vemlidy Tied to Better Bone, Kidney Safety After 1 Year
Post by: Hep Editors on December 21, 2018, 10:40:46 am

For those with hepatitis B virus (HBV), taking Gilead Sciences’ Viread (tenofovir disoproxil fumarate, or TDF) for two years and then switching to Vemlidy (tenofovir alafenamide, or TAF) was associated with improvements in measures of kidney and bone health one year after the switch.

Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco (The Liver Meeting), researchers conducted two identically designed studies that enrolled a cumulative 1,298 people with HBV, including those who were HBeAg negative and HBeAg positive.

For more...
https://www.hepmag.com/article/switch-viread-vemlidy-tied-better-bone-kidney-safety-1-year